 |
||||
| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
|
||||
| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
,
*University of Alberta, Edmonton, Alberta, Canada; University of Texas School of Public Health. Houston, Texas; 
Department of Epidemiology, Harvard School of Public Health. Boston, Massachusetts; Channing Laboratory, Brigham and Women’s Hospital. Boston, Massachusetts; and ¶Washington University School of Medicine, St. Louis, Missouri.
Correspondence to Dr. Marcello Tonelli, University of Alberta, Division of Nephrology & Immunology, 11-103C Clinical Science Building, 8440 112 Street, Edmonton, Alberta T6B 2B7, Canada. Phone: 780-407-8716; Fax: 780-407-7878;
ABSTRACT. Limited data suggest that HMG-CoA reductase inhibitors (statins) may slow loss of renal function in individuals with chronic renal insufficiency. This study was conducted to determine whether pravastatin reduced rates of loss of renal function in people with moderate chronic renal insufficiency. This was a post hoc subgroup analysis of a randomized double-blind placebo controlled trial. Data were analyzed from the CARE study (a randomized trial of pravastatin versus placebo in 4159 participants with previous myocardial infarction and total plasma cholesterol < 240 mg/dl). Participants with estimated GFR (MDRD-GFR) < 60 ml/min per 1.73 m2 body surface area at baseline were considered to have moderate chronic renal insufficiency. Multivariate regression was used to calculate rates of decline in MDRD-GFR for individuals receiving pravastatin and placebo, controlling for prospectively determined covariates that might influence rates of renal function loss. Change in renal function could be calculated in 3384 individuals, of whom 690 (20.4%) had MDRD-GFR < 60 ml/min per 1.73 m2 and were eligible for inclusion. Among all individuals with MDRD-GFR < 60 ml/min per 1.73 m2), the MDRD-GFR decline in the pravastatin group was not significantly different from that in the placebo group (0.1 ml/min per 1.73 m2/yr slower; 95% CI, -0.2 to 0.4; P = 0.49). However, there was a significant stepwise inverse relation between MDRD-GFR before treatment and slowing of renal function loss with pravastatin use, with more benefit in those with lower MDRD-GFR at baseline (P = 0.04). Rate of change in MDRD-GFR in the pravastatin group was 0.6 ml/min per 1.73 m2/yr slower than placebo (95% CI, -0.1 to 1.2; P = 0.07) in those with MDRD-GFR < 50 ml/min, and 2.5 ml/min per 1.73 m2/yr slower (95% CI, 1.4 to 3.6 slower; P = 0.0001) in those with MDRD-GFR < 40 ml/min per 1.73 m2/yr. Pravastatin also reduced rates of renal loss to a greater extent in participants with than without proteinuria at baseline (P = 0.006). It is concluded that pravastatin may slow renal function loss in individuals with moderate to severe kidney disease, especially those with proteinuria. These findings require confirmation by a large randomized trial conducted specifically in people with chronic renal insufficiency. E-mail: mtonelli@ualberta.ca
This article has been cited by other articles:
 |
|
 |
|
  R. H. Samson Author Response Vascular and Endovascular Surgery, December 1, 2009; 42(6): 621 - 621. [PDF]
|
|
|
|
 |
|
 C. A. Herzog Kidney disease in cardiology Nephrol. Dial. Transplant., January 1, 2009; 24(1): 34 - 37. [Full Text] [PDF]
|
|
|
|
 |
|
 T. I. Kassimatis and P. A. Konstantinopoulos Statins in Patients With Chronic Kidney Disease: A Double-Edged Sword? J. Am. Coll. Cardiol., November 11, 2008; 52(20): 1679 - 1679. [Full Text] [PDF]
|
|
|
|
|
|
F. C. Cormack-Aboud, P. T. Brinkkoetter, J. W. Pippin, S. J. Shankland, and R. V. Durvasula Rosuvastatin protects against podocyte apoptosis in vitro Nephrol. Dial. Transplant., September 27, 2008; (2008) gfn528v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P Hull and D. J A Goldsmith Nephrotic syndrome in adults BMJ, May 24, 2008; 336(7654): 1185 - 1189. [Full Text] [PDF]
|
|
|
|
|
|
L. Paulsen, C. Holm, J. N. Bech, J. Starklint, and E. B. Pedersen Effects of statins on renal sodium and water handling: Acute and short-term effects of atorvastatin on renal haemodynamics, tubular function, vasoactive hormones, blood pressure and pulse rate in healthy, normocholesterolemic humans Nephrol. Dial. Transplant., May 1, 2008; 23(5): 1556 - 1561. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. G. Athyros, A. I. Kakafika, K. Tziomalos, A. Karagiannis, and D. P. Mikhailidis CORONA, Statins, and Heart Failure: Who Lost the Crown? Angiology, March 1, 2008; 59(1): 5 - 8. [PDF]
|
|
|
|
 |
|
 A. M. Tershakovec, W. F. Keane, Z. Zhang, P. A. Lyle, G. B. Appel, J. B. McGill, H.-H. Parving, M. E. Cooper, S. Shahinfar, and B. M. Brenner Effect of LDL Cholesterol and Treatment With Losartan on End-Stage Renal Disease in the RENAAL Study Diabetes Care, March 1, 2008; 31(3): 445 - 447. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. RIFKIN and M. SARNAK Q: Should all patients with chronic kidney disease take a statin? Cleveland Clinic Journal of Medicine, February 1, 2008; 75(2): 118 - 120. [Full Text] [PDF]
|
|
|
|
 |
|
 I. H. de Boer, B. C. Astor, H. Kramer, W. Palmas, S. L. Seliger, M. G. Shlipak, D. S. Siscovick, M. Y. Tsai, and B. Kestenbaum Lipoprotein Abnormalities Associated with Mild Impairment of Kidney Function in the Multi-Ethnic Study of Atherosclerosis Clin. J. Am. Soc. Nephrol., January 1, 2008; 3(1): 125 - 132. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. M. Campese and J. Park HMG-CoA Reductase Inhibitors and Renal Function Clin. J. Am. Soc. Nephrol., November 1, 2007; 2(6): 1100 - 1103. [Full Text] [PDF]
|
|
|
|
|
|
J. Shepherd, J. J.P. Kastelein, V. Bittner, P. Deedwania, A. Breazna, S. Dobson, D. J. Wilson, A. Zuckerman, N. K. Wenger, and for the Treating to New Targets Investigators Effect of Intensive Lipid Lowering with Atorvastatin on Renal Function in Patients with Coronary Heart Disease: The Treating to New Targets (TNT) Study Clin. J. Am. Soc. Nephrol., November 1, 2007; 2(6): 1131 - 1139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Romayne Kurukulasuriya, G. Athappan, G. Saab, A. Whaley Connell, and J. R. Sowers Review: HMG CoA reductase inhibitors and renoprotection: the weight of the evidence Therapeutic Advances in Cardiovascular Disease, October 1, 2007; 1(1): 49 - 59. [Abstract] [PDF]
|
|
|
|
 |
|
 P. W. B. Nanayakkara, C. van Guldener, P. M. ter Wee, P. G. Scheffer, F. J. van Ittersum, J. W. Twisk, T. Teerlink, W. van Dorp, and C. D. A. Stehouwer Effect of a Treatment Strategy Consisting of Pravastatin, Vitamin E, and Homocysteine Lowering on Carotid Intima-Media Thickness, Endothelial Function, and Renal Function in Patients With Mild to Moderate Chronic Kidney Disease: Results From the Anti-Oxidant Therapy in Chronic Renal Insufficiency (ATIC) Study Arch Intern Med, June 25, 2007; 167(12): 1262 - 1270. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Garcia-Garcia, G. Briseno-Renteria, V. H. Luquin-Arellan, Z. Gao, J. Gill, and M. Tonelli Survival among Patients with Kidney Failure in Jalisco, Mexico J. Am. Soc. Nephrol., June 1, 2007; 18(6): 1922 - 1927. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. M. Wahba and R. H. Mak Obesity and Obesity-Initiated Metabolic Syndrome: Mechanistic Links to Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., May 1, 2007; 2(3): 550 - 562. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-L. Koepke, M. Weber, E. Schulze-Lohoff, B. Beirowski, S. Segerer, and O. Gross Nephroprotective effect of the HMG-CoA-reductase inhibitor cerivastatin in a mouse model of progressive renal fibrosis in Alport syndrome Nephrol. Dial. Transplant., April 1, 2007; 22(4): 1062 - 1069. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Gianella, E. Nobili, M. Abbate, C. Zoja, P. Gelosa, L. Mussoni, S. Bellosta, M. Canavesi, D. Rottoli, U. Guerrini, et al. Rosuvastatin Treatment Prevents Progressive Kidney Inflammation and Fibrosis in Stroke-Prone Rats Am. J. Pathol., April 1, 2007; 170(4): 1165 - 1177. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. G. Athyros, D. P. Mikhailidis, E. N. Liberopoulos, A. I. Kakafika, A. Karagiannis, A. A. Papageorgiou, K. Tziomalos, E. S. Ganotakis, and M. Elisaf Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: A subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study Nephrol. Dial. Transplant., January 1, 2007; 22(1): 118 - 127. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Ritz and C. Wanner Lipid Changes and Statins in Chronic Renal Insufficiency J. Am. Soc. Nephrol., December 1, 2006; 17(12_suppl_3): S226 - S230. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Atthobari, A. H. Brantsma, R. T. Gansevoort, S. T. Visser, F. W. Asselbergs, W. H. van Gilst, P. E. de Jong, L. T. W. de Jong-van den Berg, and on behalf of PREVEND study group The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study Nephrol. Dial. Transplant., November 1, 2006; 21(11): 3106 - 3114. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Tonelli Do statins protect the kidney as well as the heart? Nephrol. Dial. Transplant., November 1, 2006; 21(11): 3005 - 3006. [Full Text] [PDF]
|
|
|
|
|
|
N. I. Parikh, S.-J. Hwang, M. G. Larson, J. B. Meigs, D. Levy, and C. S. Fox Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control. Arch Intern Med, September 25, 2006; 166(17): 1884 - 1891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Molitch Management of Dyslipidemias in Patients with Diabetes and Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., September 1, 2006; 1(5): 1090 - 1099. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Tovar and D. B. Schering Management of Dyslipidemia in Special Populations Journal of Pharmacy Practice, April 1, 2006; 19(2): 63 - 78. [Abstract] [PDF]
|
|
|
|
|
|
L. M. Ruilope and J. Segura Blood pressure lowering or selection of antihypertensive agent: which is more important? Nephrol. Dial. Transplant., April 1, 2006; 21(4): 843 - 845. [Full Text] [PDF]
|
|
|
|
|
|
C. Zoccali, R. Maio, G. Tripepi, F. Mallamaci, and F. Perticone Inflammation as a Mediator of the Link between Mild to Moderate Renal Insufficiency and Endothelial Dysfunction in Essential Hypertension. J. Am. Soc. Nephrol., April 1, 2006; 17(4_suppl_2): S64 - S68. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. D'Amico Statins and Renal Diseases: From Primary Prevention to Renal Replacement Therapy. J. Am. Soc. Nephrol., April 1, 2006; 17(4_suppl_2): S148 - S152. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. D. Vaziri Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences Am J Physiol Renal Physiol, February 1, 2006; 290(2): F262 - F272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Shlipak and C. Stehman-Breen Observational Research Databases in Renal Disease J. Am. Soc. Nephrol., December 1, 2005; 16(12): 3477 - 3484. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Tonelli, C. Isles, T. Craven, A. Tonkin, M. A. Pfeffer, J. Shepherd, F. M. Sacks, C. Furberg, S. M. Cobbe, J. Simes, et al. Effect of Pravastatin on Rate of Kidney Function Loss in People With or at Risk for Coronary Disease Circulation, July 12, 2005; 112(2): 171 - 178. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kurella, J. C. Lo, and G. M. Chertow Metabolic Syndrome and the Risk for Chronic Kidney Disease among Nondiabetic Adults J. Am. Soc. Nephrol., July 1, 2005; 16(7): 2134 - 2140. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Tsirpanlis, F. Boufidou, F. Alevyzaki, and E. Psimenou Statins and progression of renal failure: is a reconsideration of clinical practice guidelines justified? Nephrol. Dial. Transplant., May 1, 2005; 20(5): 1015 - 1016. [Full Text] [PDF]
|
|
|
|
|
|
A. J. W. Branten, G. Vervoort, and J. F. M. Wetzels Serum creatinine is a poor marker of GFR in nephrotic syndrome Nephrol. Dial. Transplant., April 1, 2005; 20(4): 707 - 711. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Stuveling, S. J. L. Bakker, H. L. Hillege, P. E. de Jong, R. O. B. Gans, and D. de Zeeuw Biochemical risk markers: a novel area for better prediction of renal risk? Nephrol. Dial. Transplant., March 1, 2005; 20(3): 497 - 508. [Full Text] [PDF]
|
|
|
|
|
|
V. M. Campese, M. K. Nadim, and M. Epstein Are 3-Hydroxy-3-Methylglutaryl-CoA Reductase Inhibitors Renoprotective? J. Am. Soc. Nephrol., March 1, 2005; 16(3_suppl_1): S11 - S17. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. S. Anavekar, J. J.V. McMurray, E. J. Velazquez, S. D. Solomon, L. Kober, J.-L. Rouleau, H. D. White, R. Nordlander, A. Maggioni, K. Dickstein, et al. Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction N. Engl. J. Med., September 23, 2004; 351(13): 1285 - 1295. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Afzali, A. A. Haydar, K. Vinen, and D. J.A. Goldsmith From Finland to Fatland: Beneficial Effects of Statins for Patients with Chronic Kidney Disease J. Am. Soc. Nephrol., August 1, 2004; 15(8): 2161 - 2168. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Afzali, A. A. Haydar, K. Vinen, and D. J. A. Goldsmith Beneficial effects of statins on the kidney: the evidence moves from mouse to man Nephrol. Dial. Transplant., May 1, 2004; 19(5): 1032 - 1036. [Full Text] [PDF]
|
|
|
|
|
|
L. Vogt, G. D. Laverman, R. P. F. Dullaart, and G. Navis Lipid management in the proteinuric patient: do not overlook the importance of proteinuria reduction Nephrol. Dial. Transplant., January 1, 2004; 19(1): 5 - 8. [Full Text] [PDF]
|
|
|
|
|
|
W. A. Wilmer, B. H. Rovin, C. J. Hebert, S. V. Rao, K. Kumor, and L. A. Hebert Management of Glomerular Proteinuria: A Commentary J. Am. Soc. Nephrol., December 1, 2003; 14(12): 3217 - 3232. [Abstract] [Full Text] [PDF]
|
|
|
HOME
CURRENT ISSUE
ARCHIVES
JASN Express
ONLINE SUBMISSION
AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP |
Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673
